Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2011 | 83 | 1 | 42-47

Article title

Evaluation of Endostatin and EGF Serum Levels in Patients with Gastric Cancer


Title variants

Languages of publication



The aim of the study was to assess angiogenesis markers - endostatin and endothelial growth factor (EGF) as markers of detection of gastric carcinoma.Material and methods. The study involved 20 patients with colorectal cancer (10 women, 10 men) aged 35 - 75 years, mean age = 55 years ± 11.2 who referred to the 2nd Department of General Surgery, Medical University in Lublin between June 2008 and June 2009. The control group comprised 10 volunteers (6 women, 4 men) who underwent upper gastrointestinal (GI) endoscopy due to the reflux disease and in whom gastric cancer was not diagnosed.Results. The mean endostatin concentration in controls was 5.21 ng/mL ± 1.37. Mean concentrations in patients with gastric cancer were higher than those in controls - 5.91 ng/mL ± 1.5. The difference was not statistically significant (p= 0.714). The EGF concentration in the control group was 28.19 pg/mL ± 12.94. EGF concentrations in patients with gastric cancer were higher compared to the control group - 28.8 pg/mL ± 12.63. The difference was not statistically significant (p= 0.85). The mean concentration of endostatin before the operation was 5.91 ng/mL ± 1.5 and after surgery was 5.33 ng/mL ± 2.01, the difference was not statistically significant.Conclusions. Blood endostatin and EGF quantitative determinations probably is not useful for detection of gastric carcinoma and effectiveness of treatment.









Physical description


1 - 1 - 2011
14 - 3 - 2011


  • 2nd Department of General Surgery, Medical University in Lublin
  • Dermatology Department, Medical University in Lublin
  • Dermatology Department, Medical University in Lublin
  • 2nd Department of General Surgery, Medical University in Lublin
  • 2nd Department of General Surgery, Medical University in Lublin
  • 2nd Department of General Surgery, Medical University in Lublin


  • National Cancer Institute, U. S. National Institutes of Health; (online) (dostęp 1 listopada 2010), baza internetowa:
  • Krajowy Rejestr Nowotworów; (online) (dostęp 1 listopada 2010), baza internetowa:
  • Biuletyn Statystyczny Ministerstwa Zdrowia 2007. Centrum Systemów Informacyjnych Ochrony Zdrowia 2007; 10-11.
  • Wallner G, Ciechański A, Dąbrowski A et al.: Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer. Folia Histochem Cytobiol 2001; 39, 2: 122-23.[PubMed]
  • Ren B, Höti N, Rabasseda X et al.: The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003; 25: 215-24.[PubMed][Crossref]
  • O'Reilly MS, Boehm T, Shing Y et al.: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 1997; 88: 277-86.[Crossref]
  • Kisker O, Becker CM, Prox D et al.: Continuous Administration of Endostatin by Intraperitoneally Implanted Osmotic Pump Improves the Efficacy and Potency of Therapy in a Mouse Xenograft Tumor Model. Cancer Res 2001; 61: 7669-74.
  • Eisterer W, Jiang X, Bachelot T et al.: Unfulfilled Promise of Endostatin in a Gene Therapy-Xenotransplant Model of Human Acute Lymphocytic Leukemia. Mol Ther 2002; 5: 352-59.[Crossref]
  • Cohen S: Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Natl Acad Sci USA 1960; 46: 302-11.[Crossref]
  • Levi-Montalcini R, Cohen S: Effects of the extract of the mouse submaxillary salivary glands on the sympathetic system of mammals. Ann N Y Acad Sci 1960; 85: 324-41.
  • Massague J: Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem 1990; 263: 21393-96.
  • Gross ME, Zorbas MA, Danels YJ et al.: Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 1991; 51:1452-59.[PubMed]
  • Radinsky R, Risin S, Fan D et al.: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.[PubMed]
  • Messa C, Russo F, Caruso MG et al.: EGF, TGF-alpha, and EGFR-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37: 285-89.
  • Mayer A, Takimoto M, Fritz E: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-60.[PubMed][Crossref]
  • Kluftinger AM, Robinson BW, Quenville NF: Correlation of epidermal growth factor receptor and cerbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992; 1: 97-105.[Crossref]
  • Kuroi K, Tanaka C, Toi M: Circulating levels of endostatin in cancer patients. Oncol Rep 2001; 8:405-09.[PubMed]
  • Shaarawy M, El-Sharkawy SA: Biomarkers of Intrinsic Angiogenic and Anti-angiogenic Activity in Patients with Endometrial Hyperplasia and Endometrial Cancer. Acta Oncol 2001; 40: 513.[Crossref][PubMed]
  • Glengen N, Mosevoll KA, Bruserud O et al.: Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chomiotherapy for acute myelogenous leukemia. Int J Cancer 2002; 101: 86-94.[Crossref]
  • Hata, K, Kumar Dhar D, Kanasaki H et al.: Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res 2003; 23:1907-12.[PubMed]
  • Suzuki M, Iizasa T, Ko E et al.: Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35: 29-34.[PubMed][Crossref]
  • Dhar DK, Ono T, Yamanoi A et al.: Serum Endostatin Predicts Tumor Vascularity In Hepatocellular Carcinoma. Cancer 2002; 95: 2188-95.[Crossref][PubMed]
  • Homer JJ, Greenman J, Stafford ND: Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol 2002; 27: 32-37.[Crossref]
  • Öhlund D, Ardnor B, Öman M et al.: Expression pattern and circulating levels of endostatin in patients with pancreas cancer. Int J Cancer 2008; 122: 2805-10.[Crossref]
  • Hedayati M, Kołomecki K, Pasieka Z i wsp.: Ocena stężeń naczyniowo-śródbłonkowego czynnika wzrostu oraz endostatyny w surowicy krwi chorych z łagodnymi i złośliwymi guzami tarczycy. Onkol Pol 2005; 8, 1: 7-12.
  • Wróbel T, Mazur G, Kapelko K et al.: Endostatin serum level in acute myeloid leukemia. Neoplasma 2005; 52, 2: 182-84.[PubMed]
  • Tomaszewski J, Miturski R, Kotarski J: Concentration of epidermal growth factor (EGF) in serum of women with endometrial cancer. Gin Pol 1996; 67: 248-53.
  • Konturek A, Barczyński M, Cichoń S et al.: Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer Langenbeck's. Arch Surg 2005; 390, 3: 216-21.
  • Pawlikowski M, Cieslak D, Stepien H et al.: Elevated blood serum levels of epidermal growth factor in some patients with gastric cancer. Endokrynol Pol 1989; 40: 149-53.[PubMed]
  • Wang Y, Tian T, Hu Z et al.: EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. Breast Cancer Res Treat 2008; 111: 321-27.[PubMed][WoS][Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.